ConforMIS (CFMS) withdrew its FDA 510(k) application for the iTotal Hip device, and plans to submit a new application in 2H16.
CFMS submitted the application for the customized total hip replacement, as planned, in 2015. In light of an inability to address FDA’s review questions within an allowed review timeframe, CFMS elected to withdraw the application. The company will address FDA’s questions and conduct any associated testing before submission of a new application for 510(k) clearance of the iTotal Hip.
The company’s proprietary iFit Image-to-Implant® technology platform is presently used to develop and manufacture knee replacement implants that are individually-sized and shaped to a patient’s anatomy.
CFMS claims that its ability to provide long-term outcomes and economic efficiency data for its custom implants and technology give it an ideal edge in the era of bundled payments, part of Medicare’s Comprehensive Care for Joint Replacement/CJR program.
ConforMIS (CFMS) withdrew its FDA 510(k) application for the iTotal Hip device, and plans to submit a new application in 2H16.
CFMS submitted the application for the customized total hip replacement, as planned, in 2015. In light of an inability to address FDA's review questions within an allowed review timeframe, CFMS elected to withdraw the...
ConforMIS (CFMS) withdrew its FDA 510(k) application for the iTotal Hip device, and plans to submit a new application in 2H16.
CFMS submitted the application for the customized total hip replacement, as planned, in 2015. In light of an inability to address FDA’s review questions within an allowed review timeframe, CFMS elected to withdraw the application. The company will address FDA’s questions and conduct any associated testing before submission of a new application for 510(k) clearance of the iTotal Hip.
The company’s proprietary iFit Image-to-Implant® technology platform is presently used to develop and manufacture knee replacement implants that are individually-sized and shaped to a patient’s anatomy.
CFMS claims that its ability to provide long-term outcomes and economic efficiency data for its custom implants and technology give it an ideal edge in the era of bundled payments, part of Medicare’s Comprehensive Care for Joint Replacement/CJR program.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
